PrestoDoctor Expands Its Cannabis Telemedicine Service to Louisiana
PrestoDoctor Expands Its Cannabis Telemedicine Service to Louisiana
MESQUITE, NV / ACCESSWIRE / December 20, 2022 / Cannabis Sativa, Inc. (OTCQB:CBDS) announces that PrestoDoctor - the #1 patient-rated medical cannabis telemedicine service - now offers its online medical cannabis card service to patients in the state of Louisiana.
內華達州梅斯基特/訪問線 /2022 年 12 月 20 日/ 大麻苜蓿公司（OTCQB：CBDS）宣布，PrestoDoctor-#1 患者評級的醫療大麻遠程醫療服務-現在為路易斯安那州的患者提供其在線醫療大麻卡服務。
"Our trusted telemedicine portal is ready to provide Louisiana medical cannabis patients with easy and confidential access and education via an online appointment with a knowledgeable licensed medical doctor" said PrestoDoctor COO Rob Tankson.
PrestoDoctor 首席運營官 Rob Tankson 表示：「我們值得信賴的遠程醫療門戶已準備好通過與知識淵博的執照醫生進行在線約會，為路易斯安那州醫療大麻患者提供輕鬆，保密的訪問和教育。」
Founded in 2015, PrestoDoctor has provided experienced and compassionate telemedicine care to more than 100,000 patients in nine states and is pleased to begin offering the same quality of service to patients in Louisiana.
PrestoDoctor 成立於 2015 年，為 9 個州的 100,000 多名患者提供經驗豐富且富有同情心的遠程醫療護理，並很高興開始為路易斯安那州的患者提供相同質量的服務。
"Louisiana should produce substantial appointments and increasing revenues for PrestoDoctor, and as medical cannabis continues to be available in more states, PrestoDoctor will be seeking to help those patients by safely connecting them to doctors from the comfort of their own home through PrestoDoctor's proprietary portal" stated Cannabis Sativa CEO David Tobias.
「路易斯安那州應該為 PrestoDoctor 提供可觀的約會和增加收入，並且隨著醫用大麻繼續在更多州可用，PrestoDoctor 將尋求通過 PrestoDoctor 的專有門戶安全地將他們從舒適的家中連接到醫生來幫助這些患者」大麻苜蓿首席執行官大衛·托比亞斯說。
About PrestoDoctor
關於博前醫生
PrestoDoctor is rated the #1 online medical marijuana doctor by tens of thousands of medical cannabis patients who have received fully qualified medical marijuana recommendations. PrestoDoctor is the only service to offer patients a custom treatment plan after they have a confidential evaluation with a licensed, highly knowledgeable physician who is an expert in treatment methods, dosing levels, and cannabis products. Founded in 2015, PrestoDoctor services are available in legal medical marijuana states: California, Missouri, New York, Nevada, Oklahoma, Pennsylvania, Illinois, Iowa, Texas and now Louisiana. A HIPAA and HITECH compliant telemedicine company, PrestoDoctor is a member of the American Telemedicine Association (ATA), maintaining the highest customer satisfaction rating for any telemedicine service online with over 19,500 5-star reviews.
PrestoDoctor 被成千上萬的醫用大麻患者評為 #1 在線醫用大麻醫生，他們收到了完全合格的醫用大麻建議。PrestoDoctor 是唯一在患者與持牌，知識淵博的醫生進行保密評估後，為患者提供定制治療計劃的服務，該醫生是治療方法，劑量水平和大麻產品方面的專家。PrestoDoctor 成立於 2015 年，在合法的醫用大麻州提供服務：加利福尼亞州，密蘇里州，紐約州，內華達州，俄克拉荷馬州，賓夕法尼亞州，伊利諾伊州，愛荷華州，德克薩斯州和PreStoDoctor 是一家符合 HIPAA 和 HITECH 標準的遠程醫療公司，是美國遠程醫療協會（ATA）的成員，在任何遠程醫療服務中保持了最高的客戶滿意度評級，並獲得了超過 19,500 個 5 星評論。
About Cannabis Sativa, Inc.
關於苜蓿大麻公司
Cannabis Sativa, Inc. ("CBDS") is engaged in telehealth, and the licensing of cannabis-related intellectual property, marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. CBDS holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, a U.S. Patent for a marijuana lozenge; a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery and trade secret formulas and processes and operates subsidiary PrestoDoctor.
大麻 Sativa, Inc.（「CBDS」）從事遠程醫療，以及大麻相關的知識產權許可，為基於大麻的產品和服務的營銷和品牌，大麻相關技術服務的運營以及輔助業務活動。CBDS 擁有關厄瓜多爾苜蓿菌株的美國專利大麻錠，美國專利大麻錠劑；一種基於大麻的藥物組合物，用於通過粘膜下交付和商業秘密配方和工藝治療高血壓障礙，並運營子公司 PrestoDoctor。
Forward-Looking Statements
前瞻性陳述
This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. No assurances are, or can be given, that the parties will enter into a definitive merger agreement for any potential strategic acquisition, or that if such agreement is entered into, that the transaction would close, if at all, on the terms set forth in this release, or that the merged acquired business would be successful. Certain conditions to any closing of a potential merger acquisition would likely be outside of our control. The Company assumes no obligation to update any forward-looking statement to reflect any event or circumstance that may arise after the date of this release.
本新聞稿包含「前瞻性陳述」。雖然本新聞稿中的前瞻性陳述反映了管理層的善意判斷，但前瞻性陳述本質上會受到已知和未知的風險和不確定性的影響，這些可能導致實際結果與這些前瞻性陳述中討論的結果有很大不同。我們呼籲讀者仔細檢討和考慮我們在向證券交易委員會提交的報告中所作出的各項披露，包括試圖向有關人士提供可能影響本公司業務、財務狀況、營運結果及現金流向的風險向有關人士提供意見的風險。如果這些風險或不確定性中的一個或多個實現，或者如果相關假設證明不正確，我們的實際結果可能與預期或預期的結果有很大差異。基本假設包括但不限於持續制定有利於大麻產品生產和商業化的法例，以及公司在利用該法例方面的成功。敦促讀者不要對這些前瞻性陳述作出不當的依賴，這些陳述僅在本發布日期發表之日起發言。並無保證雙方將就任何潛在的策略性收購訂立確定合併協議，或者如果達成此類協議，即使有的話，該交易將根據本新聞稿中列出的條款完成，或者合併後獲得的業務將會成功完成。任何關閉潛在合併收購的某些條件可能超出我們的控制範圍。本公司沒有義務更新任何前瞻性聲明，以反映在本發布日期之後可能出現的任何事件或情況。
Contact Information:
聯絡資訊：
(702) 762-3123
(702) 762-3123
SOURCE: Cannabis Sativa, Inc.
來源： 大麻苜蓿, 公司.
譯文內容由第三人軟體翻譯。